Trimodulin - Biotest
Alternative Names: BT 588; BT086; IgM concentrate - Biotest; TrimoduliaLatest Information Update: 30 Jun 2023
Price :
$50 *
At a glance
- Originator Biotest AG
- Class Anti-infectives; Anti-inflammatories; Antivirals; Polyclonal antibodies
- Mechanism of Action Endotoxin inhibitors; Immunostimulants; Phagocyte stimulants; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Community-acquired pneumonia; COVID 2019 infections
Most Recent Events
- 20 Jun 2023 Phase-III clinical trials in Community-acquired pneumonia (Adjunctive treatment) in USA, Czech Republic, Belgium (IV) (NCT05722938)
- 10 Feb 2023 Biotest AG plans a phase III trial for Community-acquired pneumonia (Adjunctive therapy, In adults, In the elderly) in March 2023 (IV, Infusion) (NCT05722938)
- 06 Sep 2022 Phase-III clinical trials in COVID-2019 infections Adjunctive treatment) in Hungary (IV) (EudraCT2022-000736-37)